Brevan Howard Capital Management LP Theravance Biopharma, Inc. Transaction History

Brevan Howard Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.66 - $10.25 $142,261 - $190,363	-18,572 Reduced 62.61%	11,093 $89,000
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $41,930 - $50,175	5,058 Added 20.56%	29,665 $251,000
Q1 2024 May 15, 2024	SELL	$8.22 - $11.59 $5,433 - $7,660	-661 Reduced 2.62%	24,607 $220,000
Q4 2023 Feb 14, 2024	BUY	$8.58 - $11.4 $216,799 - $288,055	25,268 New	25,268 $284,000

129

46.5M

600

300

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $622M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Brevan Howard Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Brevan Howard Capital Management LP with notifications on news.